{
    "root": "ff54fe98-8963-4a05-83f1-084287e71d9b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Tacrolimus"
    },
    "value": "20250425",
    "ingredients": [
        {
            "name": "TACROLIMUS",
            "code": "WM0HAQ4WNM"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "tacrolimus capsule calcineurin-inhibitor immunosuppressant indicated prophylaxis organ rejection adult patients receiving allogeneic liver , kidney , heart transplants pediatric patients receiving allogeneic liver transplants combination immunosuppressants . ( 1.1 )",
    "contraindications": "intravenous ( iv ) recommended patients tolerate oral formulations ( capsules ) . ( 2.1 , 2.2 ) administer capsules consistently without food . ( 2.1 ) therapeutic monitoring recommended . ( 2.1 , 2.6 ) avoid eating grapefruit drinking grapefruit juice . ( 2.1 ) adjustments african-american patients ( 2.2 ) , hepatic renal impaired . ( 2.4 , 2.5 ) complete dosing information , full prescribing information . adult patient population initial oral ( formulation ) whole blood trough concentration range kidney transplant azathioprine 0.2 mg/kg/day capsules , divided two doses , every 12 hours month 1 3 : 7 20 ng/ml month 4 12 : 5 15 ng/ml mmf/il-2 receptor antagonist 0.1 mg/kg/day capsules , divided two doses , every 12 hours month 1 12 : 4 11 ng/ml liver transplant corticosteroids 0.1 0.15 mg/kg/day capsules , divided two doses , every 12 hours month 1 12 : 5 20 ng/ml heart transplant azathioprine mmf 0.075 mg/kg/day capsules , divided two doses , every 12 hours month 1 3 : 10 20 ng/ml month ≥ 4 : 5 15 ng/ml pediatric patient population initial oral ( formulation ) whole blood trough concentration range liver transplant 0.15 0.2 mg/kg/day capsules divided two doses , every 12 hours month 1 12 : 5 20 ng/ml mmf = mycophenolate mofetil",
    "warningsAndPrecautions": null,
    "adverseReactions": "tacrolimus contraindicated patients hypersensitivity tacrolimus . tacrolimus injection contraindicated patients hypersensitivity hco-60 ( polyoxyl 60 hydrogenated castor oil ) . hypersensitivity symptoms reported include dyspnea , rash , pruritus , acute respiratory distress syndrome [ ( 6 ) ] .",
    "indications_original": "Tacrolimus capsule is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver, kidney, or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants. ( 1.1 )",
    "contraindications_original": "Intravenous (IV) use recommended for patients who cannot tolerate oral formulations (capsules). ( 2.1 , 2.2 ) Administer capsules consistently with or without food. ( 2.1 ) Therapeutic drug monitoring is recommended. ( 2.1 , 2.6 ) Avoid eating grapefruit or drinking grapefruit juice. ( 2.1 ) See dosage adjustments for African-American patients ( 2.2 ), hepatic and renal impaired. ( 2.4 , 2.5 ) For complete dosing information, see Full Prescribing Information. ADULT Patient Population Initial Oral Dosage (formulation) Whole Blood Trough Concentration Range Kidney Transplant With azathioprine 0.2 mg/kg/day capsules, divided in two doses, every 12 hours Month 1 to 3: 7 to 20 ng/mL Month 4 to 12: 5 to 15 ng/mL With MMF/IL-2 receptor antagonist 0.1 mg/kg/day capsules, divided in two doses, every 12 hours Month 1 to 12: 4 to 11 ng/mL Liver Transplant With corticosteroids only 0.1 to 0.15 mg/kg/day capsules, divided in two doses, every 12 hours Month 1 to 12: 5 to 20 ng/mL Heart Transplant With azathioprine or MMF 0.075 mg/kg/day capsules, divided in two doses, every 12 hours Month 1 to 3: 10 to 20 ng/mL Month ≥ 4: 5 to 15 ng/mL PEDIATRIC Patient Population Initial Oral Dosage (formulation) Whole Blood Trough Concentration Range Liver Transplant 0.15 to 0.2 mg/kg/day capsules divided in two doses, every 12 hours Month 1 to 12: 5 to 20 ng/mL MMF = Mycophenolate mofetil",
    "adverseReactions_original": "Tacrolimus is contraindicated in patients with a hypersensitivity to tacrolimus. Tacrolimus injection is contraindicated in patients with a hypersensitivity to HCO-60 (polyoxyl 60 hydrogenated castor oil). Hypersensitivity symptoms reported include dyspnea, rash, pruritus, and acute respiratory distress syndrome [see Adverse Reactions (6)]."
}